Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (8261)	1/11/1999 11:52:00 PM
From: aknahow	Respond to of 17367

I appreciated your post on the model. Think however it was Robert S that began the post using his own calculations and others just accepted them as meaningless. Now I see that if done correctly the model does provide some frame of reference. BTW here is an interesting site on CD14. It is from June 98, and I don't think I posted it before but I might have. ncbi.nlm.nih.gov

To: schadenfreude who wrote (8261)	1/12/1999 5:44:00 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

Otaku>Good point on the O.5 factor, however I didnt attempt the model, RobertS did.(big difference). Yes, we did address the approval/disapproval factors way back. Actually if you use that then you use 0.3 for a p2 and get 1.6 total expected however I expect the expected to change radically this year based on clinicals. All IMO btw-I think RobertS point was that if Neuprex gets approved in all those indications then its a $7 stock by his analysis. I dont agree with that at all.